US · Healthcare · Biotechnology
EPS came in at 12.53 against a street estimate of 8.00 — a beat of 56.6%.
Analysts rate Regeneron Pharmaceuticals Inc a buy (19 buy, 5 hold, 1 sell out of 25) with an average price target of $833.54.
| Fund | Stake |
|---|---|
| BlackRock Inc | 8.53% |
| Vanguard Capital Management, LLC | 6.35% |
| State Street Corp | 4.45% |
| Dodge & Cox | 4.25% |
| JPMorgan Chase & Co | 4.11% |
| Amvescap Plc. | 3.72% |
| Franklin Resources Inc | 2.60% |
| Geode Capital Management, LLC | 2.49% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 | 2026-07-30 |
| Results announced · Q3 2026 | 2026-07-30 |
| Results announced · Q3 2026 | 2026-07-06 |
| Shareholder vote results · Q2 2026 | 2026-06-17 |
| Quarterly report · Q1 2026 | 2026-04-29 |
| Results announced · Q2 2026 | 2026-04-29 |
| Proxy statement · Q2 2026 | 2026-04-24 |
| Annual report FY2025 | 2026-02-04 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.94 / share ex-date Aug 18, 2026 · pay Aug 31, 2026 | 2026-08-18 |
| Dividend | $0.94 / share ex-date May 20, 2026 · pay Jun 4, 2026 | 2026-05-20 |
| Dividend | $0.94 / share ex-date Feb 20, 2026 · pay Mar 5, 2026 | 2026-02-20 |
| Dividend | $0.88 / share ex-date Nov 20, 2025 · pay Dec 5, 2025 | 2025-11-20 |
| Dividend | $0.88 / share ex-date Aug 18, 2025 · pay Sep 3, 2025 | 2025-08-18 |
| Announcement | Date |
|---|---|
| Acquired in-process research and development charge reported for Q2 2026 Regeneron Pharmaceuticals announced a one-time charge of approximately $127 million ($1.00 per share) in Q2 2026 related to in-process research and development (IPR&D) expenses. This charge | 2026-07-06 |
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Regeneron Pharmaceuticals Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.